Trials / Recruiting
RecruitingNCT06947980
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo Comparator | Placebo subcutaneous injection |
| BIOLOGICAL | CM512 | CM512 subcutaneous injection |
Timeline
- Start date
- 2025-06-19
- Primary completion
- 2026-07-18
- Completion
- 2026-11-07
- First posted
- 2025-04-27
- Last updated
- 2025-08-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06947980. Inclusion in this directory is not an endorsement.